Stock listing

NASDAQ:AZR Azora Therapeutics, Inc. Stock

Follow Azora Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:AZR

$3.85 USD +0.05 (+1.3%)

Close on Nov 20, 2026

Past year -48.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.56 – $3.90 USDNov 20, 2026
Volume
41,824 sharesNov 20, 2026
Market cap
$55.00M USDAt the close on Nov 20, 2026 · price × 14.29M shares outstanding
52-week range
$1.31 – $8.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$230,200 USDMedian day 43,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Azora Therapeutics, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AZR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.85+0.05+1.3%$3.75$3.90$3.5641,824
$3.80+0.135+3.7%$3.56$3.96$3.45208,735
$3.665-0.145-3.8%$3.63$3.95$3.4743,290
$3.81-0.28-6.8%$3.78$3.945$3.588,037
$4.09+0.35+9.4%$3.77$4.09$3.7610,965
$3.74+0.23+6.6%$3.59$4.035$3.42850,812
$3.51-0.25-6.6%$3.75$3.87$3.4511,011
$3.76+0.01+0.3%$3.75$3.987$3.7483,518
$3.75-0.25-6.3%$4.03$4.30$3.7431,418
$4.00+0.29+7.8%$3.91$4.00$3.75578,187
$3.71-0.34-8.4%$4.04$4.04$3.7118,500
$4.05-0.10-2.4%$3.95$4.30$3.957,000
$4.15+0.26+6.7%$4.07$4.39$3.6833,100
$3.89+0.08+2.1%$4.70$4.83$3.8043,400
$3.81-1.07-21.9%$4.71$4.94$3.02169,200
$4.88-0.17-3.4%$4.50$4.97$3.67146,900
$5.05+1.34+36.1%$3.98$5.15$3.8099,700
$3.71+0.03+0.8%$3.72$3.98$3.677,400
$3.68-0.24-6.1%$3.94$3.94$3.5911,700
$3.92-0.30-7.1%$4.15$4.28$3.9247,400
$4.22+0.11+2.7%$4.16$4.22$4.162,300
$4.11+0.29+7.6%$3.75$4.41$3.7521,500
$3.82+0.20+5.5%$3.51$3.98$3.518,400
$3.62+0.13+3.7%$3.54$3.66$3.4612,100
$3.49+0.35+11.1%$3.07$3.66$3.0756,400
$3.14+0.14+4.7%$3.00$3.30$3.0013,900
$3.00-0.29-8.8%$3.17$3.32$3.0027,400
$3.29-0.21-6.0%$3.52$3.87$3.2075,400
$3.50-0.40-10.3%$4.04$4.04$3.47167,000
$3.90-0.07-1.8%$4.03$4.06$3.903,000
$3.97-0.02-0.5%$4.02$4.05$3.924,900
$3.99+0.01+0.3%$3.91$4.09$3.914,400
$3.98-0.37-8.5%$4.38$4.50$3.9811,900
$4.35+0.23+5.6%$4.05$4.43$3.9260,000
$4.12-0.01-0.2%$4.13$4.66$3.9264,500
$4.13+0.12+3.0%$4.12$4.45$3.8613,400
$4.01-0.14-3.4%$4.16$4.29$3.9535,300
$4.15+0.11+2.7%$4.04$4.30$3.9729,300
$4.04-0.18-4.3%$4.05$4.30$3.8547,500
$4.22-0.22-5.0%$4.40$4.56$4.1233,200
$4.44+0.40+9.9%$4.00$4.64$4.0047,300
$4.04-0.16-3.8%$4.25$4.25$3.7760,900
$4.20-0.20-4.5%$4.40$4.42$4.1440,200
$4.40-0.46-9.5%$4.82$4.82$4.2343,700
$4.86-0.35-6.7%$5.23$5.23$4.5986,900
$5.21-0.03-0.6%$5.25$5.38$5.0421,600
$5.24+0.24+4.8%$5.01$5.30$5.0029,700
$5.000.000.0%$5.02$5.18$4.8029,000
$5.00+0.10+2.0%$4.94$5.18$4.8746,500
$4.90-1.10-18.3%$6.06$6.11$4.80108,500
$6.00+0.07+1.2%$5.94$6.22$5.9017,200
$5.93-0.72-10.8%$6.64$6.65$5.8748,700
$6.65-0.47-6.6%$7.01$7.20$6.3367,600
$7.12+0.46+6.9%$6.61$7.20$6.2750,100
$6.66+0.34+5.4%$6.32$6.80$6.2552,800
$6.32+0.37+6.2%$5.92$6.43$5.8053,800
$5.95+0.20+3.5%$5.80$6.17$5.5144,400
$5.75+0.15+2.7%$5.57$5.98$5.3069,900
$5.60-0.09-1.6%$5.70$5.79$5.4563,500
$5.69-0.25-4.2%$5.96$5.96$5.4553,600
$5.94+0.12+2.1%$5.84$6.07$5.5964,600
$5.82+0.42+7.8%$5.35$5.90$5.1932,100
$5.40-0.82-13.2%$6.19$6.19$4.70132,300
$6.22+0.32+5.4%$5.95$6.41$5.7481,700
$5.90+0.14+2.4%$5.81$5.94$5.3642,000

Splits

2 splits since 2023 · NASDAQ:AZR · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
1-for-25Consolidation
Ticker
NASDAQ:AZR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Azora Therapeutics, Inc. news

Azora Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 3 in all · newest Nov 19, 2026 · oldest 2026
Decks
1 deck · latest October 2026

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$33.00M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.00

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Azora Therapeutics, Inc. · NASDAQ:AZRUS$55.00MUS$33.00Mn/an/an/an/an/an/a1.00
Kazia Therapeutics Ltd · NASDAQ:KZIAUS$56.22MUS$10.36Mn/a373×n/a1.8×n/a0.0×2.31
OKYO Pharma Limited · NASDAQ:OKYOUS$56.15MUS$35.56Mn/an/an/a4.5×n/a0.0×1.02
Gwo Xi Stem Cell Applied Technology Co., Ltd. · TPEX:6704US$55.77MUS$51.65Mn/a9.1×n/a2.5×−43.0%0.3×n/a
EyeGene, Inc. · KRX:185490US$55.57MUS$26.66Mn/a8.0×n/a1.5×−391.5%0.0×n/a
Cognition Therapeutics, Inc. · NASDAQ:CGTXUS$55.37MUS$25.10Mn/an/an/a1.9×n/a0.0×2.28
AB Science SA · EURONEXT:ABUS$55.19MUS$50.54Mn/a39.2×n/an/a−132.6%n/an/a
Island Pharmaceuticals Ltd · ASX:ILAUS$54.84MUS$46.32Mn/a248×n/a6.2×n/a0.0×n/a
Anavex Life Sciences Corp. · NASDAQ:AVXLUS$54.83M−US$63.50Mn/an/an/a0.5×n/a0.0×2.39
Nordicus Partners Corp · OTC:NORDUS$54.44MUS$54.44Mn/an/an/a0.9×n/a0.0×0.45
Boundless Bio, Inc. · NASDAQ:BOLDUS$53.61M−US$9.28Mn/an/an/a0.9×n/a0.0×0.65
Median of the othersUS$55.28MUS$31.11M39.2×1.8×−132.6%0.0×1.65

Forecasts

2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
13.00 USD · Analysts' mean
EPS, year to Dec 2026
-4.94 · 1 analyst

Team and board

Officers

OfficerRole
Matt DavidsonChief Executive Officer

Board

DirectorRole
Kevin SchuylerChairman of the Board
J. Kermit AndersonDirector
Matt DavidsonChief Executive Officer
Robertson GillilandDirector
Wendy YoungIndependent Director

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close+9.4%
Q2 2026Aug 19, 2026+8.3%
Q1 2026May 11, 2026−3.5%
Q4 2025Mar 9, 20260.0%
Q3 2025Nov 14, 2025−3.1%
Q2 2025Aug 13, 2025−2.5%
Q1 2025May 15, 2025+1.5%
Q4 2024Mar 4, 2025+5.5%
Q3 2024Nov 13, 2024+11.8%
Q2 2024Aug 19, 2024+1.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024−12.1%
Q4 2023Mar 28, 2024−12.1%
Q3 2023Nov 14, 2023+5.5%
Q2 2023Aug 21, 2023−3.5%
Q1 2023May 12, 20230.0%
Q3 2022Nov 14, 2022+3.6%
Q2 2022Aug 16, 2022−5.0%
Q1 2022May 16, 2022+15.6%
Q4 2021Mar 2, 2022−3.5%
Quarter to Sep 30, 2021Nov 16, 2021+4.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck22 slidesOctober 2026

Open Decks

IPO

Went public as ADIAL PHARMACEUTICALS, INC. Priced at US$5.00 a unit on Jul 26, 2018.

Price
US$5.00 a unit
Units offered
1,464,000 units
Offering size
US$7.3 million
Underwriters' option
Up to 219,600 more units
Listing
ADIL on the Nasdaq Capital Market
Underwriters
Joseph Gunnar & Co., Dawson James Securities, Inc. · In the order on the cover
Units delivered
On or about Jul 31, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceMay 12, 2017
Filed publiclySep 7, 2017
Amended 8 timesNewest Jul 10, 2018
Shares registered with an exchangeDec 11, 2017
Declared effective by the SECJul 26, 2018
Final prospectus, with the priceJul 30, 2018

Filings

FilingFiled
424B4 · ProspectusJul 30, 2018
CERT · Exchange's certificate of listingJul 27, 2018
EFFECT · Notice that a registration is effectiveJul 26, 2018
EFFECT · Notice that a registration is effectiveJul 26, 2018
CORRESP · Letter to the SECJul 24, 2018
CORRESP · Letter to the SECJul 24, 2018
8-A12B/A · Registration of shares for listing on an exchange, amendedJul 23, 2018
FWP · Free writing prospectusJul 10, 2018
S-1/A · Registration statement, amendedJul 10, 2018
UPLOAD · Letter from the SECJul 3, 2018
All 41 filings
FilingFiled
CORRESP · Letter to the SECJul 3, 2018
S-1/A · Registration statement, amendedJul 3, 2018
S-1/A · Registration statement, amendedJun 26, 2018
CORRESP · Letter to the SECJun 25, 2018
UPLOAD · Letter from the SECJun 21, 2018
S-1/A · Registration statement, amendedJun 11, 2018
S-1/A · Registration statement, amendedApr 16, 2018
CORRESP · Letter to the SECDec 19, 2017
CORRESP · Letter to the SECDec 15, 2017
CORRESP · Letter to the SECDec 15, 2017
8-A12B · Registration of shares for listing on an exchangeDec 11, 2017
FWP · Free writing prospectusNov 27, 2017
S-1/A · Registration statement, amendedNov 22, 2017
FWP · Free writing prospectusOct 25, 2017
CORRESP · Letter to the SECOct 25, 2017
S-1/A · Registration statement, amendedOct 25, 2017
UPLOAD · Letter from the SECOct 5, 2017
FWP · Free writing prospectusSep 28, 2017
FWP · Free writing prospectusSep 25, 2017
S-1/A · Registration statement, amendedSep 25, 2017
CORRESP · Letter to the SECSep 25, 2017
UPLOAD · Letter from the SECSep 21, 2017
CORRESP · Letter to the SECSep 19, 2017
S-1 · Registration statementSep 7, 2017
DRSLTR · Letter to the SEC with a draftJul 28, 2017
DRS/A · Draft registration statement, amendedJul 28, 2017
UPLOAD · Letter from the SECJul 3, 2017
DRSLTR · Letter to the SEC with a draftJun 21, 2017
DRS/A · Draft registration statement, amendedJun 21, 2017
UPLOAD · Letter from the SECJun 12, 2017
DRS · Draft registration statementMay 12, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue0000
Research and development2.62M3.23M1.27M1.95M8.40M5.85M3.97M368.5K182.1K
Selling, general and administrative5.18M5.06M5.62M8.91M
Operating income-7.80M-8.28M-6.89M-10.9M-19.3M-10.9M-8.24M-6.99M-995.3K
Depreciation and amortization565565564564
EBITDA-7.80M-8.28M-6.89M-10.9M
Income before tax-7.98M-13.2M-7.00M-10.8M-19.5M-10.9M-8.59M-11.6M-1.14M
Income tax-502-94.1K
Net income-7.98M-13.2M-5.12M-12.7M-19.4M-10.9M-8.59M-11.6M-1.14M
Earnings per share, basic-11.93-68.01-3.60-12.71-1.04-0.87-0.87-2.44-0.35
Earnings per share, diluted-11.93-68.01-3.60-12.71-1.04-0.87-0.87-2.44-0.35

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents5.88M3.75M2.83M4.00M6.06M4.40M6.78M3.87M18.2K
Receivables41.8K
Current assets6.18M4.06M3.20M4.78M6.46M5.14M7.67M4.69M27.2K
Property, plant and equipment50.4K58.1K
Goodwill249.0K249.0K
Total assets6.67M5.04M4.74M5.73M7.47M5.49M7.68M4.70M34.5K
Accounts payable655.0K250.1K103.3K276.4K286.2K648.7K190.2K99.7K
Current liabilities1.40M975.9K653.1K1.79M2.72M1.51M539.1K258.0K1.03M
Total liabilities1.40M975.9K653.1K2.46M3.97M1.51M
Shareholders' equity5.28M4.07M4.08M3.28M3.51M3.99M7.14M4.44M-997.6K
Shares outstanding1.11M258.8K1.66M1.07M20.9M14.4M10.4M6.86M3.27M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-6.49M-6.92M-6.81M-11.2M-11.9M-7.63M-6.34M-2.50M-494.9K
Capital spending0000-64.6K
Free cash flow-6.49M-6.92M-6.81M-11.2M-12.0M
Cash from investing150.0K1.50M-34.0K-350.0K35.1K
Cash from financing8.47M7.85M4.13M9.13M13.6M5.61M9.25M6.35M390.0K
Share buybacks-1.66K
Change in cash2.13M923.4K-1.17M-2.06M1.66M-2.38M2.91M3.85M-69.7K

Open Financials

Filings

FilingDateTypeFiled with
S-3 · Registration statementNov 16, 2026Offer documentSEC
S-8 · Registration statement for employee plansNov 13, 2026Offer documentSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
3 · Initial statement of ownershipNov 10, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 10, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 10, 2026Insider tradeSEC
8-K · Current reportNov 9, 2026Management or board changeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 3, 2026Big-stake noticeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 30, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 30, 2026Insider tradeSEC
8-K · Current reportOct 28, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveOct 27, 2026Other filingsSEC
10-Q/A · Quarterly report, amendedOct 20, 2026Quarterly reportSEC
S-3/A · Registration statement, amendedOct 20, 2026Offer documentSEC
DEFA14A · Additional proxy materialOct 16, 2026Meeting noticeSEC
8-K · Current reportOct 16, 2026Current reportSEC
DEFA14A · Additional proxy materialOct 2, 2026Meeting noticeSEC
8-K · Current reportOct 2, 2026Current reportSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
DEFA14A · Additional proxy materialSep 18, 2026Meeting noticeSEC
8-K · Current reportSep 18, 2026Management or board changeSEC
DEFA14A · Additional proxy materialSep 16, 2026Meeting noticeSEC
8-K · Current reportSep 16, 2026Material contractSEC
S-3 · Registration statementAug 28, 2026Offer documentSEC
S-8 · Registration statement for employee plansAug 28, 2026Offer documentSEC
8-K · Current reportAug 25, 2026FinancingSEC
ARS · Annual report to shareholdersAug 24, 2026Annual reportSEC
DEF 14A · Proxy statementAug 24, 2026Meeting noticeSEC
8-K · Current reportAug 21, 2026Current reportSEC
8-K · Current reportAug 17, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026Management or board changeSEC
PRE 14A · Preliminary proxy statementAug 10, 2026Meeting noticeSEC
8-K/A · Current report, amendedAug 10, 2026Current reportSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 1, 2026Big-stake noticeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 29, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 24, 2026Big-stake noticeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 16, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Acquisition or disposalSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 11, 2026ResultsSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
8-K · Current reportApr 9, 2026Management or board changeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
8-K · Current reportMar 6, 2026ResultsSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 3, 2026Current reportSEC
8-K · Current reportFeb 24, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2026Big-stake noticeSEC
8-K · Current reportFeb 4, 2026Current reportSEC
8-K · Current reportJan 6, 2026Management or board changeSEC
DEF 14A · Proxy statementJan 6, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 23, 2025Meeting noticeSEC
424B5 · ProspectusDec 19, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 18, 2025Other filingsSEC
CORRESP · Letter to the SECDec 15, 2025Other filingsSEC
S-3 · Registration statementDec 12, 2025Offer documentSEC
DDec 3, 2025Other filingsSEC
8-K · Current reportDec 1, 2025Material contractSEC
8-K · Current reportNov 14, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportSep 16, 2025Current reportSEC
S-8 · Registration statement for employee plansSep 9, 2025Offer documentSEC
8-K · Current reportSep 3, 2025Current reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
424B5 · ProspectusAug 1, 2025Offer documentSEC
8-K · Current reportAug 1, 2025Material contractSEC
8-K · Current reportAug 1, 2025Management or board changeSEC
424B5 · ProspectusJul 31, 2025Offer documentSEC
8-K · Current reportJul 16, 2025Current reportSEC
8-K · Current reportJul 10, 2025Current reportSEC
DEFR14AJun 27, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeJun 23, 2025Big-stake noticeSEC
8-K · Current reportJun 18, 2025Material contractSEC
424B5 · ProspectusJun 18, 2025Offer documentSEC
PRER14AJun 17, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJun 17, 2025Other filingsSEC
8-K · Current reportJun 16, 2025Current reportSEC
S-1/A · Registration statement, amendedJun 13, 2025Offer documentSEC
CORRESP · Letter to the SECJun 12, 2025Other filingsSEC
CORRESP · Letter to the SECJun 12, 2025Other filingsSEC
ARS · Annual report to shareholdersJun 10, 2025Annual reportSEC
DEF 14A · Proxy statementJun 10, 2025Meeting noticeSEC
424B3 · ProspectusJun 10, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 10, 2025Other filingsSEC
CORRESP · Letter to the SECJun 6, 2025Other filingsSEC
S-1 · Registration statementJun 6, 2025Offer documentSEC
CORRESP · Letter to the SECJun 5, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 4, 2025Other filingsSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
S-3 · Registration statementMay 30, 2025Offer documentSEC
8-K · Current reportMay 30, 2025Current reportSEC
PRE 14A · Preliminary proxy statementMay 23, 2025Meeting noticeSEC
8-K · Current reportMay 15, 2025Current reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
DMay 13, 2025Other filingsSEC
8-K · Current reportMay 7, 2025Material contractSEC
424B5 · ProspectusMay 2, 2025Offer documentSEC
424B5 · ProspectusMay 2, 2025Offer documentSEC
8-K · Current reportMay 1, 2025Current reportSEC
UPLOAD · Letter from the SECApr 1, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftMar 27, 2025Other filingsSEC
DRS · Draft registration statementMar 27, 2025Offer documentSEC
8-K · Current reportMar 21, 2025Management or board changeSEC
8-K · Current reportMar 7, 2025Current reportSEC
8-K · Current reportMar 4, 2025ResultsSEC
10-K · Annual reportMar 4, 2025Annual reportSEC
8-K · Current reportFeb 25, 2025Current reportSEC
8-K · Current reportJan 13, 2025Current reportSEC
8-K · Current reportJan 8, 2025Current reportSEC
424B3 · ProspectusDec 31, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 31, 2024Other filingsSEC
CORRESP · Letter to the SECDec 26, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 26, 2024Other filingsSEC
S-1 · Registration statementDec 20, 2024Offer documentSEC
8-K · Current reportDec 18, 2024Material contractSEC
S-8 · Registration statement for employee plansDec 12, 2024Offer documentSEC
8-K · Current reportDec 6, 2024Management or board changeSEC
4 · Change in ownershipDec 5, 2024Insider tradeSEC
8-K · Current reportNov 18, 2024Current reportSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 18, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024Management or board changeSEC
8-K · Current reportNov 5, 2024Management or board changeSEC
ARS · Annual report to shareholdersSep 27, 2024Annual reportSEC
DEF 14A · Proxy statementSep 27, 2024Meeting noticeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportApr 26, 2024Management or board changeSEC
424B3 · ProspectusApr 23, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 22, 2024Other filingsSEC
424B5 · ProspectusApr 18, 2024Offer documentSEC
8-K · Current reportApr 18, 2024Material contractSEC
CORRESP · Letter to the SECApr 17, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 17, 2024Other filingsSEC
8-K · Current reportApr 16, 2024Management or board changeSEC
S-3 · Registration statementApr 12, 2024Offer documentSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
DMar 14, 2024Other filingsSEC
8-K · Current reportMar 6, 2024Material contractSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
424B5 · ProspectusJan 25, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 25, 2024Other filingsSEC
CORRESP · Letter to the SECJan 22, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 19, 2024Other filingsSEC
8-K · Current reportJan 18, 2024Management or board changeSEC
8-K · Current reportJan 16, 2024Meeting outcomeSEC
S-3 · Registration statementJan 12, 2024Offer documentSEC
DEFA14A · Additional proxy materialDec 14, 2023Meeting noticeSEC
S-8 · Registration statement for employee plansDec 12, 2023Offer documentSEC
DEF 14A · Proxy statementDec 8, 2023Meeting noticeSEC
8-K · Current reportNov 29, 2023Current reportSEC
8-K · Current reportNov 28, 2023Current reportSEC
PRE 14A · Preliminary proxy statementNov 24, 2023Meeting noticeSEC
424B3 · ProspectusNov 20, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 20, 2023Other filingsSEC
CORRESP · Letter to the SECNov 15, 2023Other filingsSEC
8-K · Current reportNov 14, 2023ResultsSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
UPLOAD · Letter from the SECNov 14, 2023Other filingsSEC
S-1 · Registration statementNov 8, 2023Offer documentSEC
8-K · Current reportNov 6, 2023Management or board changeSEC
10-Q/A · Quarterly report, amendedOct 30, 2023Quarterly reportSEC
8-K/A · Current report, amendedOct 30, 2023Acquisition or disposalSEC
NT 10-Q/A · Late filing notice, amendedOct 30, 2023Explanation requestSEC
DOct 26, 2023Other filingsSEC
8-K · Current reportOct 24, 2023Material contractSEC

This page holds 200 of 583 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Azora Therapeutics, Inc.’s releases · as of Nov 16, 2026

Common shares
14,286,312
Fully diluted
14,326,312

Fully diluted

LineSharesAs of
Common shares14,286,312
Options and RSUs40,000Nov 16, 2026

Warrants and options

Lot
Stock options · US$3.81 · expire about Nov 2036

Share count over time

CountShares
Nov 22, 202614,286,312

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Cary Claiborne
Other companies: Adial Pharmaceuticals, Inc (Chief Executive Officer, Director · Since at least Apr 7, 2026); NeuroSense Therapeutics Ltd. (Board Member · Since at least Mar 18, 2026)
Chief Executive Officer, Director · Since at least May 29, 2025
Robertson Gilliland
Other companies: Adial Pharmaceuticals, Inc (Director · Since at least Apr 7, 2026)
Director · Since at least May 23, 2023
Bankole A JohnsonDirector · Jul 26, 2018 – May 23, 2023 · Past
James W Newman JrDirector · Since at least Jul 26, 2018
J. Kermit AndersonDirector · Since at least May 29, 2025
Joseph TruluckChief Financial Officer · Jul 26, 2018 – Mar 25, 2024 · Past
Julie SaikiChief Strategy Officer · Since at least Nov 2, 2026
Kevin SchuylerChairman of the Board · Since at least Nov 5, 2026
Matt DavidsonChief Executive Officer · Since at least Nov 4, 2026
Wendy YoungIndependent Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Azora Therapeutics, Inc.